KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer

eLife

Volumn 6, Issue , 2017, Pages

  Krall, Elsa B ^a,b,c,f   Wang, Belinda ^a,b,c   Munoz, Diana M ^d   Ilic, Nina ^a,b,c   Raghavan, Srivatsan ^a,b,c   Niederst, Matthew J ^d   Yu, Kristine ^d   Ruddy, David A ^d   Aguirre, Andrew J ^a,b,c   Kim, Jong Wook ^a,b,c   Redig, Amanda J ^a,c   Gainor, Justin F ^e   Williams, Juliet A ^d   Asara, John M ^c   Doench, John G ^b   Janne, Pasi A ^a,c   Shaw, Alice T ^e   McDonald, Robert E ^d   Engelman, Jeffrey A ^d   Stegmeier, Frank ^d   Schlabach, Michael R ^d   Hahn, William C ^a,b,c   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f KSQ THERAPEUTICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; ANAPLASTIC LYMPHOMA KINASE INHIBITOR; B RAF KINASE; CERITINIB; CRISPR ASSOCIATED PROTEIN; CRIZOTINIB; ERLOTINIB; GLUTATHIONE; GLYCINE HYDROXYMETHYLTRANSFERASE; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; KEAP1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL FRACTIONATION; CONTROLLED STUDY; CRISPR CAS SYSTEM; GENE DELETION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LUNG CANCER; MASS SPECTROMETRY; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROCESS OPTIMIZATION; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; UBIQUITINATION; WESTERN BLOTTING; XENOTRANSPLANTATION; CELL PROLIFERATION; GENE KNOCKOUT; GENETICS; LUNG TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME INHIBITORS; GENE KNOCKOUT TECHNIQUES; HUMANS; KELCH-LIKE ECH-ASSOCIATED PROTEIN 1; LUNG NEOPLASMS;

EID: 85013410562     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.18970     Document Type: Article

References (51)

1. Aguirre AJ, Meyers RM, Weir BA, Vazquez F, Zhang CZ, Ben-David U, Cook A, Ha G, Harrington WF, Doshi MB, Kost-Alimova M, Gill S, Xu H, Ali LD, Jiang G, Pantel S, Lee Y, Goodale A, Cherniack AD, Oh C, et al. 2016. Genomic copy number dictates a Gene-Independent cell response to CRISPR/Cas9 Targeting. Cancer Discovery 6:914-929. doi: 10.1158/2159-8290.CD-16-0154, PMID: 27260156
2. Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF, Chiang A, Yang G, Ouerfelli O, Kris MG, Ladanyi M, Miller VA, Pao W. 2006. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clinical Cancer Research 12:6494-6501. doi: 10.1158/1078-0432.CCR-06-1570, PMID: 17085664
3. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, Morais P, Meltzer J, Korejwa A, Jané-Valbuena J, Mapa FA, et al. 2012. The cancer cell line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603-607. doi: 10.1038/nature11003, PMID: 22460905
4. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R. 2007. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12:395-402. doi: 10.1016/j.ccr.2007.08.030, PMID: 17936563
5. Blumenschein GR, Smit EF, Planchard D, Kim DW, Cadranel J, De Pas T, Dunphy F, Udud K, Ahn MJ, Hanna NH, Kim JH, Mazieres J, Kim SW, Baas P, Rappold E, Redhu S, Puski A, Wu FS, Jänne PA. 2015. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†. Annals of Oncology 26:894-901. doi: 10.1093/annonc/mdv072, PMID: 25722381
6. Brinkman EK, Chen T, Amendola M, van Steensel B. 2014. Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Research 42:e168. doi: 10.1093/nar/gku936, PMID: 25300484
7. Cancer Genome Atlas Research Network. 2014. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511:543-550. doi: 10.1038/nature13385, PMID: 25079552
8. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N. 2012. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discovery 2:401-404. doi: 10.1158/ 2159-8290.CD-12-0095, PMID: 22588877
9. Chen B, Gilbert LA, Cimini BA, Schnitzbauer J, Zhang W, Li GW, Park J, Blackburn EH, Weissman JS, Qi LS, Huang B. 2013. Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system. Cell 155:1479-1491. doi: 10.1016/j.cell.2013.12.001, PMID: 24360272
10. Chio II, Jafarnejad SM, Ponz-Sarvise M, Park Y, Rivera K, Palm W, Wilson J, Sangar V, Hao Y, Öhlund D, Wright K, Filippini D, Lee EJ, Da Silva B, Schoepfer C, Wilkinson JE, Buscaglia JM, DeNicola GM, Tiriac H, Hammell M, et al. 2016. NRF2 promotes tumor maintenance by modulating mRNA translation in pancreatic cancer. Cell 166:963-976. doi: 10.1016/j.cell.2016.06.056, PMID: 27477511
11. Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD, Della Pelle P, Dias-Santagata D, Hung KE, Flaherty KT, Piris A, Wargo JA, Settleman J, Mino-Kenudson M, Engelman JA. 2012. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discovery 2:227-235. doi: 10.1158/2159-8290.CD-11-0341, PMID: 22448344
12. Corcoran RB, Cheng KA, Hata AN, Faber AC, Ebi H, Coffee EM, Greninger P, Brown RD, Godfrey JT, Cohoon TJ, Song Y, Lifshits E, Hung KE, Shioda T, Dias-Santagata D, Singh A, Settleman J, Benes CH, Mino-Kenudson M, Wong KK, et al. 2013. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 23:121-128. doi: 10.1016/j.ccr.2012.11.007, PMID: 23245996
13. Crystal AS, Shaw AT, Sequist LV, Friboulet L, Niederst MJ, Lockerman EL, Frias RL, Gainor JF, Amzallag A, Greninger P, Lee D, Kalsy A, Gomez-Caraballo M, Elamine L, Howe E, Hur W, Lifshits E, Robinson HE, Katayama R, Faber AC, et al. 2014. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 346:1480-1486. doi: 10.1126/science.1254721, PMID: 25394791
14. DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES, Scrimieri F, Winter JM, Hruban RH, Iacobuzio-Donahue C, Kern SE, Blair IA, Tuveson DA. 2011. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475:106-109. doi: 10.1038/ nature10189, PMID: 21734707
15. DeNicola GM, Chen PH, Mullarky E, Sudderth JA, Hu Z, Wu D, Tang H, Xie Y, Asara JM, Huffman KE, Wistuba II, Minna JD, DeBerardinis RJ, Cantley LC. 2015. NRF2 regulates serine biosynthesis in non-small cell lung cancer. Nature Genetics 47:1475-1481. doi: 10.1038/ng.3421, PMID: 26482881
16. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, Fulton L, Fulton RS, Zhang Q, Wendl MC, Lawrence MS, Larson DE, Chen K, Dooling DJ, Sabo A, Hawes AC, et al. 2008. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455:1069-1075. doi: 10.1038/nature07423, PMID: 18948947
17. Doench JG, Hartenian E, Graham DB, Tothova Z, Hegde M, Smith I, Sullender M, Ebert BL, Xavier RJ, Root DE. 2014. Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. Nature Biotechnology 32:1262-1267. doi: 10.1038/nbt.3026, PMID: 25184501
18. Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, Smith I, Tothova Z, Wilen C, Orchard R, Virgin HW, Listgarten J, Root DE. 2016. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nature Biotechnology 34:184-191. doi: 10.1038/nbt.3437, PMID: 26780180
19. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA. 2007. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043. doi: 10.1126/science.1141478, PMID: 17463250
20. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, Ding M, Bamford S, Cole C, Ward S, Kok CY, Jia M, De T, Teague JW, Stratton MR, McDermott U, Campbell PJ. 2015. COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. Nucleic Acids Research 43:D805-D811. doi: 10.1093/nar/ gku1075, PMID: 25355519
21. Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R, Dagogo-Jack I, Gadgeel S, Schultz K, Singh M, Chin E, Parks M, Lee D, DiCecca RH, Lockerman E, Huynh T, Logan J, Ritterhouse LL, Le LP, Muniappan A, et al. 2016. Molecular mechanisms of resistance to first-and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. Cancer Discovery 6:1118-1133. doi: 10.1158/2159-8290.CD-16-0596, PMID: 27432227
22. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N. 2013. Integrative analysis of complex Cancer genomics and clinical profiles using the cBioPortal. Science Signaling 6:pl1. doi: 10.1126/scisignal.2004088, PMID: 23550210
23. Hayes JD, Dinkova-Kostova AT. 2014. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends in Biochemical Sciences 39:199-218. doi: 10.1016/j.tibs.2014.02.002, PMID: 24647116
24. Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, Wolf J, Raje NS, Diamond EL, Hollebecque A, Gervais R, Elez-Fernandez ME, Italiano A, Hofheinz RD, Hidalgo M, Chan E, Schuler M, Lasserre SF, Makrutzki M, Sirzen F, et al. 2015. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. New England Journal of Medicine 373:726-736. doi: 10.1056/NEJMoa1502309, PMID: 26287849
25. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, Sougnez C, Auclair D, Lawrence MS, Stojanov P, Cibulskis K, Choi K, de Waal L, Sharifnia T, Brooks A, Greulich H, et al. 2012. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150:1107-1120. doi: 10.1016/j.cell.2012.08.029, PMID: 22980975
26. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, et al. 2010. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468:968-972. doi: 10.1038/nature09627, PMID: 21107320
27. Johannessen CM, Johnson LA, Piccioni F, Townes A, Frederick DT, Donahue MK, Narayan R, Flaherty KT, Wargo JA, Root DE, Garraway LA. 2013. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature 504:138-142. doi: 10.1038/nature12688, PMID: 24185007
28. Kim E, Ilic N, Shrestha Y, Zou L, Kamburov A, Zhu C, Yang X, Lubonja R, Tran N, Nguyen C, Lawrence MS, Piccioni F, Bagul M, Doench JG, Chouinard CR, Wu X, Hogstrom L, Natoli T, Tamayo P, Horn H, et al. 2016. Systematic functional interrogation of rare cancer variants identifies oncogenic Alleles. Cancer Discovery 6:714-726. doi: 10.1158/2159-8290.CD-16-0160, PMID: 27147599
29. Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, Chiba T, Igarashi K, Yamamoto M. 2004. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Molecular and Cellular Biology 24:7130-7139. doi: 10.1128/MCB.24.16.7130-7139.2004, PMID: 15282312
30. Kosaka T, Yatabe Y, Endoh H, Yoshida K, Hida T, Tsuboi M, Tada H, Kuwano H, Mitsudomi T. 2006. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clinical Cancer Research 12:5764-5769. doi: 10.1158/1078-0432.CCR-06-0714, PMID: 17020982
31. Manchado E, Weissmueller S, Morris JP, Chen CC, Wullenkord R, Lujambio A, de Stanchina E, Poirier JT, Gainor JF, Corcoran RB, Engelman JA, Rudin CM, Rosen N, Lowe SW. 2016. A combinatorial strategy for treating KRAS-mutant lung cancer. Nature 534:647-651. doi: 10.1038/nature18600, PMID: 27338794
32. Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, Aburatani H, Yamamoto M, Motohashi H. 2012. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 22:66-79. doi: 10.1016/j.ccr.2012.05.016, PMID: 22789539
33. Munoz DM, Cassiani PJ, Li L, Billy E, Korn JM, Jones MD, Golji J, Ruddy DA, Yu K, McAllister G, DeWeck A, Abramowski D, Wan J, Shirley MD, Neshat SY, Rakiec D, de Beaumont R, Weber O, Kauffmann A, McDonald ER, et al. 2016. CRISPR screens provide a comprehensive assessment of cancer vulnerabilities but generate False-Positive hits for highly amplified genomic regions. Cancer Discovery 6:900-913. doi: 10.1158/2159-8290. CD-16-0178, PMID: 27260157
34. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS. 2010. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973-977. doi: 10.1038/nature09626, PMID: 21107323
35. Ohta T, Iijima K, Miyamoto M, Nakahara I, Tanaka H, Ohtsuji M, Suzuki T, Kobayashi A, Yokota J, Sakiyama T, Shibata T, Yamamoto M, Hirohashi S. 2008. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Research 68:1303-1309. doi: 10.1158/0008-5472.CAN-07-5003, PMID: 183165 92
36. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R. 2012. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483:100-103. doi: 10.1038/nature10868, PMID: 22281684
37. Rudin CM, Hong K, Streit M. 2013. Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer. Journal of Thoracic Oncology 8:e41-e42. doi: 10.1097/JTO.0b013e31828bb1b3, PMID: 23524406
38. Sanjana NE, Shalem O, Zhang F. 2014. Improved vectors and genome-wide libraries for CRISPR screening. Nature Methods 11:783-784. doi: 10.1038/nmeth.3047, PMID: 25075903
39. Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS, Heckl D, Ebert BL, Root DE, Doench JG, Zhang F. 2014. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343:84-87. doi: 10. 1126/science.1247005, PMID: 24336571
40. Shibata T, Kokubu A, Gotoh M, Ojima H, Ohta T, Yamamoto M, Hirohashi S. 2008a. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 135:1358-1368. doi: 10.1053/j.gastro.2008.06.082, PMID: 18692501
41. Shibata T, Ohta T, Tong KI, Kokubu A, Odogawa R, Tsuta K, Asamura H, Yamamoto M, Hirohashi S. 2008b. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. PNAS 105:13568-13573. doi: 10.1073/pnas.0806268105, PMID: 18757741
42. Sun Z, Huang Z, Zhang DD. 2009. Phosphorylation of Nrf2 at multiple sites by MAP kinases has a limited contribution in modulating the Nrf2-dependent antioxidant response. PLoS One 4:e6588. doi: 10.1371/journal. pone.0006588, PMID: 19668370
43. Sun C, Hobor S, Bertotti A, Zecchin D, Huang S, Galimi F, Cottino F, Prahallad A, Grernrum W, Tzani A, Schlicker A, Wessels LF, Smit EF, Thunnissen E, Halonen P, Lieftink C, Beijersbergen RL, Di Nicolantonio F, Bardelli A, Trusolino L, et al. 2014. Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. Cell Reports 7:86-93. doi: 10.1016/j.celrep.2014.02.045, PMID: 24685132
44. Tang J, Salama R, Gadgeel SM, Sarkar FH, Ahmad A. 2013. Erlotinib resistance in lung Cancer: current progress and future perspectives. Frontiers in Pharmacology 4:15. doi: 10.3389/fphar.2013.00015, PMID: 23407898
45. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, Macconaill LE, Hahn WC, Meyerson M, Garraway LA. 2011. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. Journal of Clinical Oncology 29:3085-3096. doi: 10.1200/JCO.2010.33.2312, PMID: 21383288
46. Wang XJ, Sun Z, Villeneuve NF, Zhang S, Zhao F, Li Y, Chen W, Yi X, Zheng W, Wondrak GT, Wong PK, Zhang DD. 2008. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 29:1235-1243. doi: 10.1093/carcin/bgn095, PMID: 18413364
47. Wang T, Wei JJ, Sabatini DM, Lander ES. 2014. Genetic screens in human cells using the CRISPR-Cas9 system. Science 343:80-84. doi: 10.1126/science.1246981, PMID: 24336569
48. Whittaker SR, Theurillat JP, Van Allen E, Wagle N, Hsiao J, Cowley GS, Schadendorf D, Root DE, Garraway LA. 2013. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discovery 3:350-362. doi: 10.1158/2159-8290.CD-12-0470, PMID: 23288408
49. Wilson FH, Johannessen CM, Piccioni F, Tamayo P, Kim JW, Van Allen EM, Corsello SM, Capelletti M, Calles A, Butaney M, Sharifnia T, Gabriel SB, Mesirov JP, Hahn WC, Engelman JA, Meyerson M, Root DE, Jänne PA, Garraway LA. 2015. A functional landscape of resistance to ALK inhibition in lung cancer. Cancer Cell 27:397-408. doi: 10.1016/j.ccell.2015.02.005, PMID: 25759024
50. Yuan M, Breitkopf SB, Yang X, Asara JM. 2012. A positive/negative ion-switching, targeted mass spectrometry-based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue. Nature Protocols 7:872-881. doi: 10.1038/nprot.2012.024, PMID: 22498707
51. Zhang P, Singh A, Yegnasubramanian S, Esopi D, Kombairaju P, Bodas M, Wu H, Bova SG, Biswal S. 2010. Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Molecular Cancer Therapeutics 9:336-346. doi: 10.1158/1535-7163.MCT-09-0589, PMID: 20124447